Metsera responds to Pfizer lawsuit, defends board process in Novo bid dispute
Pfizer’s GLP-1 lawsuit tests biosimilar ambitions and contract guardrails.
Novo Nordisk
Novo’s unsolicited bid for Metsera challenges Pfizer pact
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
NanoVation Therapeutics Partners with Novo Nordisk to Develop Genetic Medicines for Cardiometabolic and Rare Diseases
Overview of the Deal:NanoVation Therapeutics has entered into a multi-year partnership with Novo Nordisk to develop cutting-edge genetic medicines that target cardiometabolic and rare diseases. Announced on September 18, 2024, this collaboration will leverage NanoVation’s long-circulating lipid nanoparticle (lcLNP™) technology, which enables RNA delivery to cells outside the liver, combined with Novo Nordisk’s expertise in … Read more